Makoto Kurano1, Akiko Suzuki1, Asuka Inoue1, Yasunori Tokuhara1, Kuniyuki Kano1, Hirotaka Matsumoto1, Koji Igarashi1, Ryunosuke Ohkawa1, Kazuhiro Nakamura1, Tomotaka Dohi1, Katsumi Miyauchi1, Hiroyuki Daida1, Kazuhisa Tsukamoto1, Hitoshi Ikeda1, Junken Aoki1, Yutaka Yatomi2. 1. From the Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan (M.K., A.S., H.I., Y.Y.); Core Research for Evolutional Science and Technology (CREST) (M.K., H.I., J.A., Y.Y.) and Precursory Research for Embryonic Science and Technology (PRESTO) (A.I.), Japan Science and Technology Agency (JST), Saitama, Japan; Laboratory of Molecular and Cellular Biochemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Miyagi, Japan (A.I., K.K., H.M., J.A.); Department of Clinical Laboratory, The University of Tokyo Hospital, Tokyo, Japan (Y.T., R.O., K.N., H.I., Y.Y.); Laboratory of Pathology, Department of Medical Technology, Kagawa Prefectural University of Health Sciences, Kagawa, Japan (Y.T.); Bioscience Division, Reagent Development Department, AIA Research Group, TOSOH Corporation, Kanagawa, Japan (K.I.); Department of Cardiovascular Medicine, Juntendo University School of Medicine, Tokyo, Japan (T.D., K.M., H.D.); and Department of Metabolism, Diabetes and Nephrology, Preparatory Office for Aizu Medical Center, Fukushima Medical University, Fukushima, Japan (K.T.). 2. From the Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan (M.K., A.S., H.I., Y.Y.); Core Research for Evolutional Science and Technology (CREST) (M.K., H.I., J.A., Y.Y.) and Precursory Research for Embryonic Science and Technology (PRESTO) (A.I.), Japan Science and Technology Agency (JST), Saitama, Japan; Laboratory of Molecular and Cellular Biochemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Miyagi, Japan (A.I., K.K., H.M., J.A.); Department of Clinical Laboratory, The University of Tokyo Hospital, Tokyo, Japan (Y.T., R.O., K.N., H.I., Y.Y.); Laboratory of Pathology, Department of Medical Technology, Kagawa Prefectural University of Health Sciences, Kagawa, Japan (Y.T.); Bioscience Division, Reagent Development Department, AIA Research Group, TOSOH Corporation, Kanagawa, Japan (K.I.); Department of Cardiovascular Medicine, Juntendo University School of Medicine, Tokyo, Japan (T.D., K.M., H.D.); and Department of Metabolism, Diabetes and Nephrology, Preparatory Office for Aizu Medical Center, Fukushima Medical University, Fukushima, Japan (K.T.). yatoyuta-tky@umin.ac.jp.
Abstract
OBJECTIVE: Lysophosphatidic acids (LPA) have important roles in the field of vascular biology and are derived mainly from lysophosphatidylcholine via autotaxin. However, in our previous study, only the plasma LPA levels, and not the serum autotaxin levels, increased in patients with acute coronary syndrome (ACS). The aim of this study was to elucidate the pathway by which LPA is increased in patients with ACS. APPROACH AND RESULTS: We measured the plasma lysophospholipids species in 141 consecutive patients undergoing coronary angiography (ACS, n=38; stable angina pectoris, n=71; angiographically normal coronary arteries, n=32) using a liquid chromatography-tandem mass spectrometry analysis. Among the ACS subjects, notable increases in the 22:6 LPA, 18:2 LPA, and 20:4 LPA levels were observed. The in vitro experiments revealed that serum incubation mainly increased the 18:2 LPA level, whereas platelet activation increased the 20:4 LPA level. Minor lysophospholipids other than LPA were also elevated in ACS subjects and were well correlated with the corresponding LPA species, including 22:6 LPA. A multiple regression analysis also revealed that lysophosphatidylinositol, lysophosphatidylcholine, lysophosphatidylethanolamine, and lysophosphatidylglycerol were independent explanatory variables for several LPA species. CONCLUSIONS: Specific LPA species, especially long-chain unsaturated LPA, were elevated in ACS patients, along with the corresponding minor lysophospholipids. The elevation of these LPA species might be mainly caused by presently unidentified LPA-producing pathway(s). Minor lysophospholipids might be involved in the generation of LPA, especially 22:6 LPA, and in the pathogenesis of ACS.
OBJECTIVE:Lysophosphatidic acids (LPA) have important roles in the field of vascular biology and are derived mainly from lysophosphatidylcholine via autotaxin. However, in our previous study, only the plasma LPA levels, and not the serum autotaxin levels, increased in patients with acute coronary syndrome (ACS). The aim of this study was to elucidate the pathway by which LPA is increased in patients with ACS. APPROACH AND RESULTS: We measured the plasma lysophospholipids species in 141 consecutive patients undergoing coronary angiography (ACS, n=38; stable angina pectoris, n=71; angiographically normal coronary arteries, n=32) using a liquid chromatography-tandem mass spectrometry analysis. Among the ACS subjects, notable increases in the 22:6 LPA, 18:2 LPA, and 20:4 LPA levels were observed. The in vitro experiments revealed that serum incubation mainly increased the 18:2 LPA level, whereas platelet activation increased the 20:4 LPA level. Minor lysophospholipids other than LPA were also elevated in ACS subjects and were well correlated with the corresponding LPA species, including 22:6 LPA. A multiple regression analysis also revealed that lysophosphatidylinositol, lysophosphatidylcholine, lysophosphatidylethanolamine, and lysophosphatidylglycerol were independent explanatory variables for several LPA species. CONCLUSIONS: Specific LPA species, especially long-chain unsaturated LPA, were elevated in ACS patients, along with the corresponding minor lysophospholipids. The elevation of these LPA species might be mainly caused by presently unidentified LPA-producing pathway(s). Minor lysophospholipids might be involved in the generation of LPA, especially 22:6 LPA, and in the pathogenesis of ACS.
Authors: Xinyuan Li; Pu Fang; William Y Yang; Kylie Chan; Muriel Lavallee; Keman Xu; Tracy Gao; Hong Wang; Xiaofeng Yang Journal: Can J Physiol Pharmacol Date: 2016-11-05 Impact factor: 2.273
Authors: Maria P Kraemer; Guogen Mao; Courtney Hammill; Baoxiang Yan; Yu Li; Fredrick Onono; Susan S Smyth; Andrew J Morris Journal: J Lipid Res Date: 2019-09-04 Impact factor: 5.922
Authors: Xin Wang; Ya-Feng Li; Gayani Nanayakkara; Ying Shao; Bin Liang; Lauren Cole; William Y Yang; Xinyuan Li; Ramon Cueto; Jun Yu; Hong Wang; Xiao-Feng Yang Journal: J Cardiovasc Transl Res Date: 2016-05-26 Impact factor: 4.132
Authors: Dawid S Chabowski; Andrew O Kadlec; Karima Ait-Aissa; Joseph C Hockenberry; Paul J Pearson; Andreas M Beyer; David D Gutterman Journal: Br J Pharmacol Date: 2018-10-11 Impact factor: 8.739
Authors: Lenche Kostadinova; Carey L Shive; Chelsey Judge; Elizabeth Zebrowski; Anita Compan; Kelsey Rife; Amy Hirsch; Yngve Falck-Ytter; Daniela M Schlatzer; Xiaolin Li; Mark R Chance; Benigno Rodriguez; Daniel L Popkin; Donald D Anthony Journal: J Infect Dis Date: 2016-08-17 Impact factor: 5.226